{"organizations": [], "uuid": "c5f1dc0709bf08060cfebadf9a0052996f840709", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-novartis-says-data-reinforces-cose/brief-novartis-says-data-reinforces-cosentyx-effectiveness-idUSFWN1PB014", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis says data reinforces ‍Cosentyx effectiveness", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-16T08:19:00.000+02:00", "replies_count": 0, "uuid": "c5f1dc0709bf08060cfebadf9a0052996f840709"}, "author": "", "url": "https://www.reuters.com/article/brief-novartis-says-data-reinforces-cose/brief-novartis-says-data-reinforces-cosentyx-effectiveness-idUSFWN1PB014", "ord_in_thread": 0, "title": "BRIEF-Novartis says data reinforces ‍Cosentyx effectiveness", "locations": [], "entities": {"persons": [{"name": "reut", "sentiment": "negative"}, {"name": "michael shields", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cosentyx", "sentiment": "negative"}, {"name": "novartis ag", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Novartis AG:\n* NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS\n* ‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​\n* ‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)\n ", "external_links": [], "published": "2018-01-16T08:19:00.000+02:00", "crawled": "2018-01-16T08:38:59.017+02:00", "highlightTitle": ""}